Literature DB >> 18277811

Increased mortality in African Americans with idiopathic pulmonary arterial hypertension.

Kala K Davis1, David E Lilienfeld, Ramona L Doyle.   

Abstract

BACKGROUND: Idiopathic pulmonary arterial hypertension (IPAH) is a progressive disorder that usually culminates in right ventricular failure and death without treatment.
OBJECTIVE: To assess mortality trends by race and gender for idiopathic pulmonary arterial hypertension in the United States from 1994-1998.
METHODS: The U.S. National Center for Health Statistics data for the years 1994-1998 was reviewed for deaths in which the underlying cause was primary pulmonary hypertension (ICD-9 code 416.0), now known as IPAH. The age, gender, race and state of residence of the deceased were abstracted from the Centers for Disease Control Wonder System (http://wonder.cdc.gov). Average annual age-adjusted region-, race- and gender-specific rates were then calculated.
RESULTS: African-American women demonstrated the highest mortality rates for IPAH across all age groups compared to other racial and gender groups. No geographical differences in mortality rates were noted. An increase in mortality rates with advancing age was observed in all racial and gender groups, with the highest mortality rates for IPAH noted in the elderly. DISCUSSION: African Americans with IPAH exhibit a substantially increased mortality compared with Caucasians, particularly African-American women.

Entities:  

Mesh:

Year:  2008        PMID: 18277811     DOI: 10.1016/s0027-9684(15)31177-9

Source DB:  PubMed          Journal:  J Natl Med Assoc        ISSN: 0027-9684            Impact factor:   1.798


  17 in total

1.  International Classification of Diseases coding changes lead to profound declines in reported idiopathic pulmonary arterial hypertension mortality and hospitalizations: implications for database studies.

Authors:  Jeffrey Link; Craig Glazer; Fernando Torres; Kelly Chin
Journal:  Chest       Date:  2010-08-19       Impact factor: 9.410

2.  Characterization of connective tissue disease-associated pulmonary arterial hypertension from REVEAL: identifying systemic sclerosis as a unique phenotype.

Authors:  Lorinda Chung; Juliana Liu; Lori Parsons; Paul M Hassoun; Michael McGoon; David B Badesch; Dave P Miller; Mark R Nicolls; Roham T Zamanian
Journal:  Chest       Date:  2010-05-27       Impact factor: 9.410

3.  Race and sex differences in response to endothelin receptor antagonists for pulmonary arterial hypertension.

Authors:  Nicole B Gabler; Benjamin French; Brian L Strom; Ziyue Liu; Harold I Palevsky; Darren B Taichman; Steven M Kawut; Scott D Halpern
Journal:  Chest       Date:  2011-09-22       Impact factor: 9.410

4.  Association of Borderline Pulmonary Hypertension With Mortality and Hospitalization in a Large Patient Cohort: Insights From the Veterans Affairs Clinical Assessment, Reporting, and Tracking Program.

Authors:  Bradley A Maron; Edward Hess; Thomas M Maddox; Alexander R Opotowsky; Ryan J Tedford; Tim Lahm; Karen E Joynt; Daniel J Kass; Thomas Stephens; Maggie A Stanislawski; Erik R Swenson; Ronald H Goldstein; Jane A Leopold; Roham T Zamanian; Jean M Elwing; Mary E Plomondon; Gary K Grunwald; Anna E Barón; John S Rumsfeld; Gaurav Choudhary
Journal:  Circulation       Date:  2016-02-12       Impact factor: 29.690

5.  Variable prevalence of pulmonary hypertension in patients with advanced interstitial pneumonia.

Authors:  Nevins W Todd; Sachin Lavania; Myung H Park; Aldo T Iacono; Teri J Franks; Jeffrey R Galvin; Jean Jeudy; Edward J Britt; Irina G Luzina; Jeffrey D Hasday; Sergei P Atamas
Journal:  J Heart Lung Transplant       Date:  2010-02       Impact factor: 10.247

6.  Sex and menopause differences in response to tadalafil: 6-minute walk distance and time to clinical worsening.

Authors:  Jennifer Rusiecki; Youlan Rao; Jody Cleveland; Zachary Rhinehart; Hunter C Champion; Michael A Mathier
Journal:  Pulm Circ       Date:  2015-12       Impact factor: 3.017

7.  Oestradiol metabolism and androgen receptor genotypes are associated with right ventricular function.

Authors:  Corey E Ventetuolo; Nandita Mitra; Fei Wan; Ani Manichaikul; R Graham Barr; Craig Johnson; David A Bluemke; Joao A C Lima; Hari Tandri; Pamela Ouyang; Steven M Kawut
Journal:  Eur Respir J       Date:  2015-12-02       Impact factor: 16.671

Review 8.  Health Disparities in Patients with Pulmonary Arterial Hypertension: A Blueprint for Action. An Official American Thoracic Society Statement.

Authors:  Arunabh Talwar; Joe G N Garcia; Halley Tsai; Matthew Moreno; Tim Lahm; Roham T Zamanian; Roberto Machado; Steven M Kawut; Mona Selej; Stephen Mathai; Laura Hoyt D'Anna; Sonu Sahni; Erik J Rodriquez; Richard Channick; Karen Fagan; Michael Gray; Jessica Armstrong; Josanna Rodriguez Lopez; Vinicio de Jesus Perez
Journal:  Am J Respir Crit Care Med       Date:  2017-10-15       Impact factor: 21.405

9.  Severity of systemic sclerosis-associated pulmonary arterial hypertension in African Americans.

Authors:  Isabel Blanco; Stephen Mathai; Majid Shafiq; Danielle Boyce; Todd M Kolb; Hala Chami; Laura K Hummers; Traci Housten; Neal Chaisson; Ari L Zaiman; Fredrick M Wigley; Ryan J Tedford; David A Kass; Rachel Damico; Reda E Girgis; Paul M Hassoun
Journal:  Medicine (Baltimore)       Date:  2014-07       Impact factor: 1.889

10.  The Evolution of Risk Assessment in Pulmonary Arterial Hypertension.

Authors:  Sandhya Murthy; Raymond Benza
Journal:  Methodist Debakey Cardiovasc J       Date:  2021-07-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.